MOC-亮氨酸 | 74761-37-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: MOC-亮氨酸
• 英文名称: (S)-2-(methoxycarbonylamino)-4-methylpentanoic acid
• 英文别名: (methoxycarbonyl)-L-leucine；N-Carbomethoxy-L-leucine；(2S)-2-(methoxycarbonylamino)-4-methylpentanoic acid
• CAS: 74761-37-8
• 化学式: C₈H₁₅NO₄
• 分子量: 189.211
• InChiKey: NPRGOLCTGVFFGS-LURJTMIESA-N

物化性质

• 沸点：
  328.4±25.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  MOC-亮氨酸 在 三溴化磷 作用下， 以 乙醚 为溶剂， 以59%的产率得到L-leucine N-carboxyanhydride
  参考文献：
  名称：

  Friedel-Crafts .alpha.-aminoacylation of alkylbenzene with a chiral N-carboxy-.alpha.-amino acid anhydride without loss of chirality

  摘要：

  A Friedel-Crafts-type alpha-aminoacylation of alkylbenzene with N-carboxy anhydrides Of five L-alpha-amino acids was developed. Five new alpha-aminoalkyl p-methylphenyl ketones and other alpha-aminoalkyl aryl ketones were obtained and isolated as free bases or hydrochloride salts. The chiralities of the original L-alpha-amino acids were retained during this acylation.

  DOI：

  10.1021/jo00052a059
• 作为产物：
  描述：

  L-亮氨酸叔丁酯盐酸盐 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 MOC-亮氨酸
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies

  摘要：

  The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (k(obs)/[I]) ranging from 60 to 280 000 M-1 s(-1) and antiviral EC50's which approach 0.15 mu M. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (k(obs)/[I] = 800 000 M-1 s(-1)) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 mu M). A 1.9 Angstrom crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-8 3CP is also detailed.

  DOI：

  10.1021/jm9800696
• 作为试剂：
  描述：

  sodium hydroxide 、 L-亮氨酸 、 disodium;carbonate 、 氯甲酸甲酯 在 ice water 、 乙醚 、 盐酸 、 2-Me THF 、 magnesium sulfate 、 二氯甲烷 、 DCM MeOH AcOH 、 MOC-亮氨酸 作用下， 反应 15.0h， 以resulting in N-methoxycarbonyl-L-leucine (1.9 g, 32%)的产率得到MOC-亮氨酸
  参考文献：
  名称：

  Benzimidazole-imidazole derivatives

  摘要：

  公式I包括立体化学异构体形式及其盐、溶剂化物，用于抑制丙型肝炎病毒复制的抑制剂，其中R和R'各自独立地为—CR1R2R3、芳基、杂芳基或杂C4-6环烷基，其中芳基和杂芳基可以选择性地被1或2个卤素和甲基取代。本发明还涉及制备所述化合物的工艺、含有它们的制药组合物以及它们在丙型肝炎病毒治疗中的应用。

  公开号：

  US20140107172A1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011050146A1

  公开（公告）日：2011-04-28

  Disclosed are compounds of Formula (I). Also disclosed are pharmaceutical compositions comprising the compounds, and methods for treating HCV invention by administration of the compounds.

  揭示了化合物的化学式（I）。还揭示了包含这些化合物的药物组合物，以及通过给药这些化合物来治疗HCV的方法。
• [EN] PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] DÉRIVÉS DE N5-MÉTHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE PEPTIDOMIMÉTIQUES, DÉRIVÉS DE TRIAZASPIRO[4.14]NONADÉCANE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2021188620A1

  公开（公告）日：2021-09-23

  Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

  肽拟态N5-甲基-N2-(壬酰基-L-亮氨酰基)-L-谷氨酸衍生物，三唑螺[4.14]十九烷衍生物以及类似化合物用于抑制生物样本或患者中诺如病毒和冠状病毒的复制，用于减少生物样本或患者中诺如病毒或冠状病毒的数量，以及用于治疗患者中的诺如病毒和冠状病毒，包括向所述生物样本或患者施用由公式I或II表示的化合物的安全有效量，或其药用可接受盐。本描述公开了典型化合物的合成和特性，以及其药理数据（例如，第99页至第271页；例1至例3；化合物A1至A104和B1至B66；表A至表E）。
• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012048421A1

  公开（公告）日：2012-04-19

  Compounds of Formula (I) and (II) wherein R1, R2, R3, R6, A and A' are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.

  式(I)和式(II)化合物，其中R1、R2、R3、R6、A和A'如本文所定义。这些化合物作为HCV编码的NS5A蛋白功能的抑制剂，对于治疗丙型肝炎病毒感染具有用途。
• Anti-Viral Compounds
  申请人：Donner Pamela L.

  公开号：US20100267634A1

  公开（公告）日：2010-10-21

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  本发明描述了在抑制丙型肝炎病毒("HCV")复制方面有效的化合物。这项发明还涉及到制造这类化合物的过程、包含这类化合物的组合物，以及使用这类化合物治疗HCV感染的方法。